FIELD: chemistry.
SUBSTANCE: present invention relates to antibodies and polynucleotides encoding them, which can be used to prevent, control or reduce the activity of the complement pathway. Invention is Bb factor antibody containing a heavy chain and a light chain, the specified antibody binds to factor Bb with greater affinity than with factor B, and inhibits complement-dependent hemolysis, and where the light chain contains an amino acid sequence selected from the group consisting of SEQ ID NO: 8–11, and the heavy chain contains an amino acid sequence selected from the group consisting of SEQ ID NO: 12–15, or the light chain contains an amino acid sequence selected from the group consisting of SEQ ID NO: 24–27, and the heavy chain contains an amino acid sequence selected from the group consisting of SEQ ID NO: 28–31.
EFFECT: invention relates to a pharmaceutical composition for treating or preventing an eye disease.
11 cl, 3 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO COMPLEMENT COMPONENT C5 | 2015 |
|
RU2693430C2 |
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
| BLOCKING ANTI-Dkk-1 ANTIBODIES AND APPLICATIONS THEREOF | 2010 |
|
RU2548817C2 |
| BINDING PROTEINS AND METHODS FOR USE THEREOF | 2015 |
|
RU2701434C2 |
| ANTIBODIES TO GLUCAGON RECEPTOR AND THEREOF APPLICATION | 2009 |
|
RU2562110C2 |
| IL-4 AND/OR IL-13 BINDING ANTIBODIES AND USING THEM | 2008 |
|
RU2580049C2 |
| STRUCTURES AIMED AT AFP/MHC PEPTIDE COMPLEXES AND TYPES OF THEIR USE | 2016 |
|
RU2754041C2 |
| ANTIBODIES AGAINST FACTOR D AND THEIR USE | 2018 |
|
RU2799044C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS | 2011 |
|
RU2533809C9 |
